Galapagos N.V.
GLPG
Cena:
$ 27.47
-0.30 (-1.08%)
Valuace
70
Růst
30
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
GALAPAGOS RECEIVES TRANSPARENCY NOTIFICATION FROM BANK OF AMERICA
16-02-2026
MECHELEN, BELGIUM ; FEBRUARY 16, 2026, 22:01 CET; REGULATED INFORMATION – GALAPAGOS NV (EURONEXT &...
Více zde
GALAPAGOS ANNOUNCES BOARD DECISION TO INITIATE WIND-DOWN OF CELL THERAPY ACTIVITIES
05-01-2026
MECHELEN, BELGIUM ; JANUARY 5, 2026, 22:01 CET; GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY ANNOUNC...
Více zde
GALAPAGOS PRESENTED NEW ATALANTA-1 CELL THERAPY DATA IN MCL AT ASH 2025
08-12-2025
HIGH COMPLETE RESPONSE RATES AND MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY, WITH DURABLE RESPONSES, ...
Více zde
GALAPAGOS RECEIVES TRANSPARENCY NOTIFICATIONS FROM BANK OF AMERICA
26-11-2025
MECHELEN, BELGIUM ; NOVEMBER 26, 2025, 07:30 CET; REGULATED INFORMATION – GALAPAGOS NV (EURONEXT &...
Více zde
GALAPAGOS TO PRESENT NEW DATA FROM CELL THERAPY PROGRAM AT ASH 2025
03-11-2025
ORAL PRESENTATION OF GLPG5101 DATA FROM THE ATALANTA-1 STUDY IN PATIENTS WITH HIGH-RISK RELAPSED/REF...
Více zde
GALAPAGOS TO PRESENT IN VITRO DATA AT ACR CONVERGENCE 2025 SUGGESTING DIFFERENTIATION OF GLPG3667 FROM OTHER TYK2 INHIBITORS
23-10-2025
MECHELEN, BELGIUM ; OCTOBER 23, 2025, 22:01 CET; GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY ANNOUN...
Více zde
GALAPAGOS ANNOUNCES INTENTION TO WIND DOWN CELL THERAPY BUSINESS AS PART OF THE COMPANY'S ONGOING TRANSFORMATION
21-10-2025
INTENTION FOLLOWS COMPREHENSIVE STRATEGIC REVIEW PROCESS AND WOULD REPRESENT THE OPTIMAL CAPITAL ALL...
Více zde
GALAPAGOS ANNOUNCES APPOINTMENT OF FRED BLAKESLEE AS GENERAL COUNSEL
16-10-2025
MECHELEN, BELGIUM; OCTOBER 16, 2025, 22:01 CET; GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY ANNOUNC...
Více zde
GALAPAGOS PROVIDES UPDATE ON STRATEGIC ALTERNATIVES FOR ITS CELL THERAPY BUSINESS
01-10-2025
MECHELEN, BELGIUM ; OCTOBER 1, 2025, 22:01 CET; GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) AND ITS BOARD...
Více zde
GALAPAGOS CREATES NEW SUBSCRIPTION RIGHT PLAN
07-08-2025
MECHELEN, BELGIUM; AUGUST 7, 2025, 22.01 CET; REGULATED INFORMATION – GALAPAGOS NV (EURONEXT &...
Více zde
GALAPAGOS NV ANNOUNCES U.S. FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO GLPG5101 FOR THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
06-08-2025
MECHELEN, BELGIUM; AUGUST 6, 2025, 7:30 CET; REGULATED INFORMATION – INSIDE INFORMATION – GALAPA...
Více zde
GALAPAGOS BOLSTER LEADERSHIP TEAM WITH SEASONED LIFE SCIENCES EXECUTIVES TO ACCELERATE BUSINESS TRANSFORMATION
23-07-2025
APPOINTS SOOIN KWON AS CHIEF BUSINESS OFFICER AND DAN GROSSMAN AS CHIEF STRATEGY OFFICER BOTH EXECUT...
Více zde
GALAPAGOS WELCOMES SEASONED PHARMACEUTICAL EXECUTIVES DAWN SVORONOS AND JANE GRIFFITHS TO ITS BOARD OF DIRECTORS
23-07-2025
NEW DIRECTORS BRING DEEP COMMERCIAL, OPERATIONAL, AND TRANSACTION EXPERIENCE TO THE BOARD MECHELEN, ...
Více zde
GALAPAGOS REPORTS HALF-YEAR 2025 FINANCIAL RESULTS AND PROVIDES SECOND QUARTER BUSINESS UPDATE
23-07-2025
APPOINTMENTS OF NEW CEO, CFO, AND SEASONED BUSINESS DEVELOPMENT LEADERS WITH PROVEN TRACK RECORDS OF...
Více zde
GALAPAGOS APPOINTS AARON COX AS CHIEF FINANCIAL OFFICER
23-06-2025
FORMER HORIZON CFO JOINS GALAPAGOS WITH DEEP EXPERTISE IN INTERNATIONAL CORPORATE FINANCE, M&A, BUSI...
Více zde
GALAPAGOS PRESENTED NEW DATA AT ICML 2025 FROM COHORT 3 OF ATALANTA-1 IN RELAPSED/REFRACTORY INDOLENT NHL PATIENTS, DEMONSTRATING HIGH COMPLETE RESPONSE AND MRD NEGATIVITY RATES WITH CAR-T CANDIDATE GLPG5101
18-06-2025
OF THE 34 PATIENTS ENROLLED IN COHORT 3 OF THE ATALANTA-1 PHASE 1/2 STUDY, 32 RECEIVED GLPG5101; 94%...
Více zde
GALAPAGOS TO PRESENT NEW ATALANTA-1 CAR-T DATA AT EHA 2025, HIGHLIGHTING LOW TOXICITY AND RAPID, DECENTRALIZED DELIVERY OF FRESH, EARLY-MEMORY-ENRICHED GLPG5101 IN R/R NHL
12-06-2025
DATA REPORTED FROM THE ONGOING ATALANTA-1 PHASE 1/2 STUDY IN A HEAVILY PRETREATED RELAPSED REFRACTOR...
Více zde
GALAPAGOS CREATES NEW SUBSCRIPTION RIGHT PLAN
27-05-2025
MECHELEN, BELGIUM; MAY 27, 2025, 22:30 CET; REGULATED INFORMATION – GALAPAGOS NV (EURONEXT & NA...
Více zde
GALAPAGOS ANNOUNCES STRATEGIC UPDATE ON PROPOSED SEPARATION, EXECUTIVE LEADERSHIP TRANSITION AND BOARD CHANGES
13-05-2025
GALAPAGOS TO RE-EVALUATE THE IMPLEMENTATION OF THE PREVIOUSLY ANNOUNCED SEPARATION FOLLOWING REGULAT...
Více zde
GALAPAGOS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS, RECENT BUSINESS HIGHLIGHTS AND NEAR-TERM CATALYSTS
23-04-2025
FIRST U.S. PATIENT DOSED IN ATALANTA-1 STUDY OF GLPG5101 MANTLE CELL LYMPHOMA (MCL), A HIGH-UNMET-NE...
Více zde
GALAPAGOS ANNOUNCES DEPARTURE OF THAD HUSTON, CFO AND COO, AS OF AUGUST 1, 2025
15-04-2025
MECHELEN, BELGIUM; APRIL 15, 2025, 07:30 CET; REGULATED INFORMATION – INSIDE INFORMATION – GALAP...
Více zde
GALAPAGOS PUBLISHES 2024 ANNUAL REPORT AND ANNOUNCES ANNUAL SHAREHOLDERS' MEETING
27-03-2025
MECHELEN, BELGIUM; MARCH 27, 2025, 21:01 CET; REGULATED INFORMATION – GALAPAGOS NV (EURONEXT & NAS...
Více zde
GALAPAGOS TO PRESENT AT UPCOMING INVESTOR CONFERENCES
24-02-2025
MECHELEN, BELGIUM; FEBRUARY 24, 2025, 22:01 CET – GALAPAGOS NV (EURONEXT & NASDAQ: GLPG), A GLOBAL...
Více zde
GALAPAGOS RECEIVES TRANSPARENCY NOTIFICATION AND 13D FILING FROM TANG CAPITAL
17-02-2025
MECHELEN, BELGIUM; FEBRUARY 17, 2025, 22:01 CET; REGULATED INFORMATION – GALAPAGOS NV (EURONEXT & ...
Více zde
GALAPAGOS REPORTS FULL YEAR 2024 RESULTS AND PROVIDES FOURTH QUARTER BUSINESS UPDATE
12-02-2025
COMPELLING CLINICAL RESULTS FOR GLPG5101 IN THREE NHL INDICATIONS UNDERSCORE POTENTIAL OF INNOVATIVE...
Více zde
GALAPAGOS TO UNLOCK SHAREHOLDER VALUE BY DECLARING ITS INTENT TO SEPARATE INTO TWO PUBLICLY TRADED ENTITIES
08-01-2025
GALAPAGOS INTENDS TO CREATE A NEW COMPANY WITH APPROXIMATELY €2.45 BILLION IN CASH DEDICATED TO BU...
Více zde
GALAPAGOS TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
07-01-2025
MECHELEN, BELGIUM; JANUARY 7, 2025, 22:01 CET; GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY ANNOUNCE...
Více zde
GALAPAGOS ANNOUNCES ENCOURAGING NEW RESULTS FROM ONGOING PHASE 1/2 STUDY OF CD19 CAR T-CELL THERAPY, GLPG5101, IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
07-12-2024
MECHELEN, BELGIUM; DECEMBER 7, 2024, 18:30 CET; GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY ANNOUNC...
Více zde
GALAPAGOS TO PRESENT RESULTS OF PIONEERING INNOVATION IN CANCER CELL THERAPY AT ASH 2024
05-11-2024
MECHELEN, BELGIUM; NOVEMBER 5, 2024, 22:01 CET; GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY ANNOUNC...
Více zde
GALAPAGOS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
30-10-2024
WEBCAST PRESENTATION ON OCTOBER 31, 2024, AT 1 3 :00 CET / 8:00 AM ET, WWW.GLPG.CO...
Více zde
Dokumenty nejsou k dispozici
